Status:
COMPLETED
First Line Ovarian Cancer Treatment - Cohort Study
Lead Sponsor:
ARCAGY/ GINECO GROUP
Collaborating Sponsors:
Roche Pharma AG
Conditions:
Epithelial Ovarian Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of bevacizumab (Avastin ®)
Detailed Description
Population: Patients aged 18 years and older with an epithelial ovarian cancer, fallopian tube or primary peritoneal or witch it was decided to initiate a process comprising of Bevacizumab (Avastin ®)...
Eligibility Criteria
Inclusion
- Patients aged 18 years and over,
- Patients with an epithelial ovarian cancer, fallopian tube or peritoneal who will receive bevacizumab (Avastin ®) in first-line therapy
- Patients should be informed of the study orally and should not have any objection their data to be processed.
Exclusion
- Patient participation in a clinical trial
- Patient non-affiliated to a social security scheme.
Key Trial Info
Start Date :
April 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT01832415
Start Date
April 1 2013
End Date
March 1 2016
Last Update
March 17 2016
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Paul Papin
Angers, France
2
Clinique Tivoli
Bordeaux, France
3
Institut Bergonié
Bordeaux, France
4
Centre jean Perrin
Clermont-Ferrand, France